These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24855723)

  • 1. The authors respond.
    Eagle D; Buell R; Vacirca J
    Oncology (Williston Park); 2014 Mar; 28(3):178, C3. PubMed ID: 24855723
    [No Abstract]   [Full Text] [Related]  

  • 2. A different view of the 340B program.
    Chapman R
    Oncology (Williston Park); 2014 Mar; 28(3):178. PubMed ID: 24855722
    [No Abstract]   [Full Text] [Related]  

  • 3. The 340b drug discount program: oncology's optical illusion.
    Eagle D; Buell RL; Vacirca J
    Oncology (Williston Park); 2013 Nov; 27(11):1068, 1070, 1072. PubMed ID: 24575533
    [No Abstract]   [Full Text] [Related]  

  • 4. Change ahead for cancer drug funding.
    Lancet Haematol; 2015 Feb; 2(2):e47. PubMed ID: 26687606
    [No Abstract]   [Full Text] [Related]  

  • 5. US oncologists call for government regulation to curb drug price rises.
    McCarthy M
    BMJ; 2015 Jul; 351():h4063. PubMed ID: 26208848
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
    Ragupathy R; Jameson M
    N Z Med J; 2016 Aug; 129(1440):22-4. PubMed ID: 27538036
    [No Abstract]   [Full Text] [Related]  

  • 7. India spurns cancer patents.
    Hayden EC
    Nature; 2013 Aug; 500(7462):266. PubMed ID: 23955214
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer drugs fund receives boost but will no longer fund "overpriced" drugs.
    Hawkes N
    BMJ; 2014 Sep; 349():g5382. PubMed ID: 25180006
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug costs: how much is too much?
    Rice M
    Eur J Cancer; 2007 Apr; 43(6):971. PubMed ID: 17514796
    [No Abstract]   [Full Text] [Related]  

  • 10. Rising cancer drug costs in the USA.
    Burki TK
    Lancet Oncol; 2017 Nov; 18(11):e652. PubMed ID: 29066009
    [No Abstract]   [Full Text] [Related]  

  • 11. Soaring price of cancer drugs leads plans to new approaches.
    Sipkoff M
    Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
    [No Abstract]   [Full Text] [Related]  

  • 12. UK Cancer Drugs Fund to reassess 42 agents.
    Cagney H
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638560
    [No Abstract]   [Full Text] [Related]  

  • 13. Limits on Medicare's ability to control rising spending on cancer drugs.
    Bach PB
    N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
    [No Abstract]   [Full Text] [Related]  

  • 14. NICE and the challenge of cancer drugs.
    Raftery J
    BMJ; 2009 Jan; 338():b67. PubMed ID: 19141502
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer charity demands extension of drug fund despite criticisms it is unfair.
    Limb M
    BMJ; 2014 Oct; 349():g6507. PubMed ID: 25354675
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer drugs dropped from 'unsustainable' fund list.
    Nurs Stand; 2015 Sep; 30(4):10. PubMed ID: 26394942
    [No Abstract]   [Full Text] [Related]  

  • 17. UnitedHealthcare's bold effort to deal with cancer drug costs.
    Burns J
    Manag Care; 2011 Jan; 20(1):12-4, 16. PubMed ID: 21309397
    [No Abstract]   [Full Text] [Related]  

  • 18. Exorbitant drug prices harm research.
    Prescrire Int; 2015 Oct; 24(164):251. PubMed ID: 26594733
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy parity laws: a remedy for high drug costs?
    Wang B; Joffe S; Kesselheim AS
    JAMA Intern Med; 2014 Nov; 174(11):1721-2. PubMed ID: 25243936
    [No Abstract]   [Full Text] [Related]  

  • 20. Actual costs of cancer drugs in 15 European countries.
    van Harten WH; Wind A; de Paoli P; Saghatchian M; Oberst S
    Lancet Oncol; 2016 Jan; 17(1):18-20. PubMed ID: 26670093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.